Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
AstraZeneca
Boehringer Ingelheim
Baxter
Mallinckrodt

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Danoprevir

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Danoprevir?

Danoprevir is an investigational drug.

There have been 31 clinical trials for Danoprevir. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Hepatitis C, Chronic, Hepatitis C, and Hepatitis. The leading clinical trial sponsors are Hoffmann-La Roche, Ascletis Pharmaceuticals Co., Ltd., and [disabled in preview].

There are twenty-eight US patents protecting this investigational drug and four hundred and eighty-nine international patents.

Recent Clinical Trials for Danoprevir
TitleSponsorPhase
Pharmacokinetics and Safety of Ravidasvir in Combination With Danoprevir/r in Healthy Volunteers ChinaAscletis Pharmaceuticals Co., Ltd.Phase 1
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r in Treatment-naive, Non-cirrhotic, Genotype1 CHC Patients.Ascletis Pharmaceuticals Co., Ltd.Phase 2/Phase 3
Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers ChinaAscletis Pharmaceuticals Co., Ltd.Phase 1

See all Danoprevir clinical trials

Clinical Trial Summary for Danoprevir

Top disease conditions for Danoprevir
Top clinical trial sponsors for Danoprevir

See all Danoprevir clinical trials

US Patents for Danoprevir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Danoprevir   Start Trial Method for treating HCV AbbVie Inc. (North Chicago, IL)   Start Trial
Danoprevir   Start Trial Macrocyclic compounds as inhibitors of viral replication Intermune, Inc. (Brisbane, CA)   Start Trial
Danoprevir   Start Trial Macrocyclic inhibitors of hepatitis C virus replication InterMune, Inc. (Brisbane, CA)   Start Trial
Danoprevir   Start Trial Process for the preparation of a macrocycle Roche Palo Alto LLC (South San Francisco, CA)   Start Trial
Danoprevir   Start Trial Ruthenium complexes as catalysts for metathesis reactions Roche Palo Alto LLC (South San Francisco, CA)   Start Trial
Danoprevir   Start Trial Macrocyclic inhibitors of hepatitis C virus replication InterMune, Inc. (Brisbane, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Danoprevir

Drugname Country Document Number Estimated Expiration Related US Patent
Danoprevir Australia 2014239563 2033-03-14   Start Trial
Danoprevir Australia 2015240754 2033-03-14   Start Trial
Danoprevir Australia 2016202823 2033-03-14   Start Trial
Danoprevir Australia 2016291154 2033-03-14   Start Trial
Danoprevir Australia 2017248487 2033-03-14   Start Trial
Danoprevir Australia 2018201011 2033-03-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKesson
Merck
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.